Importantly, the detection of autoantibodies was based not on full-length antigens, but on carefully selected synthetic epitopic regions from the human proteins DAB1, AIFM1, and SURF1. This deliberate focus on immunodominant fragments—previously validated in acute COVID-19—was designed to pinpoint the specific sequences most likely to trigger an autoimmune response in the context of PCS as well. The gene discussed is SURF1; the disease is COVID-19.